1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Caduet® (amlodipine besylate/atorvastatin calcium) Tablets-
2.5 mg/40 mg, 5 mg/40 mg, 5 mg/80 mg, and 10 mg/80 mg

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>CADUET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product for the treatment of high blood pressure (hypertension), high cholesterol (hyperlipidemia).</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance:
2.5 mg/40 mg: White film-coated tablets
5 mg/40 mg: White film-coated tablets
5 mg/80 mg: White film-coated tablets
10 mg/80 mg: Blue film-coated tablets

Statement of Hazard:
Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
Short Term: May cause eye irritation; May be harmful if swallowed. (based on components).
Antihypertensive drug: has blood pressure-lowering properties

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver.
Adverse effects associated with therapeutic use of amlodipine include headache, swelling, dizziness, flushing, and palpitations. The most common adverse effects seen with the therapeutic use of atorvastatin include constipation, flatulence, upset stomach, and abdominal pain. Therapeutic use of atorvastatin has been associated with changes in liver function and muscle aches or weakness.

Known Clinical Effects:

EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous
3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine besylate</td>
<td>111470-99-6</td>
<td>Not listed</td>
<td>N;R51</td>
<td>0.87-1.74</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Xn;R22</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Xi;R41</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin calcium</td>
<td>134523-03-8</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>10.85</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Silicon dioxide, NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>471-34-1</td>
<td>207-439-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry blue</td>
<td>NOT ASSIGNED</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry white</td>
<td>NOT ASSIGNED</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry clear</td>
<td>NOT ASSIGNED</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>74811-65-7</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>9004-64-2</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not determined
6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

**General Handling:** Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Releases to the environment should be avoided. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

**Storage Conditions:** Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

No Occupational Exposure Limit (OEL) or Short Term Exposure Limit (STEL) has been identified.

**Amlodipine besylate**
- **Pfizer OEL TWA-8 Hr:** 100 µg/m³

**Atorvastatin calcium**
- **Pfizer OEL TWA-8 Hr:** 50 µg/m³

**Starch, pregelatinized**
- **ACGIH Threshold Limit Value (TWA)**: 10 mg/m³ TWA
- **Australia TWA**: 10 mg/m³
- **Belgium OEL - TWA**: Listed
- **Bulgaria OEL - TWA**: Listed
- **Czech Republic OEL - TWA**: Listed
- **Greece OEL - TWA**: Listed
- **Ireland OEL - TWAs**: Listed
- **OSHA - Final PELS - TWAs:** 15 mg/m³ total
- **Portugal OEL - TWA**: Listed
- **Spain OEL - TWA**: Listed

**Silicon dioxide, NF**
- **Australia TWA**: 2 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Austria OEL - MAKs Listed
Czech Republic OEL - TWA Listed
Estonia OEL - TWA Listed
Germany - TRGS 900 - TWAs 4 mg/m³
Germany (DFG) - MAK 4 mg/m³ MAK
Ireland OEL - TWAs Listed
Latvia OEL - TWA Listed
OSHA - Final PELs - Table Z-3 Mineral D: - (80)/(% SiO2) mg/m³ TWA
Slovenia OEL - TWA Listed

Microcrystalline cellulose
ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA
Australia TWA 10 mg/m³
Belgium OEL - TWA Listed
Estonia OEL - TWA Listed
France OEL - TWA Listed
Ireland OEL - TWAs Listed
Latvia OEL - TWA Listed
OSHA - Final PELS - TWAs: 15 mg/m³ total
5 mg/m³
Portugal OEL - TWA Listed
Romania OEL - TWA Listed
Spain OEL - TWA Listed

Calcium carbonate
Australia TWA 10 mg/m³
Belgium OEL - TWA Listed
Bulgaria OEL - TWA Listed
Czech Republic OEL - TWA Listed
Estonia OEL - TWA Listed
France OEL - TWA Listed
Greece OEL - TWA Listed
Hungary OEL - TWA Listed
Ireland OEL - TWAs Listed
Latvia OEL - TWA Listed
OSHA - Final PELS - TWAs: 15 mg/m³ total
5 mg/m³
Poland OEL - TWA Listed
Portugal OEL - TWA Listed
Spain OEL - TWA Listed

Magnesium stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA
Australia TWA 10 mg/m³
Belgium OEL - TWA Listed
Ireland OEL - TWAs Listed
Lithuania OEL - TWA Listed
Portugal OEL - TWA Listed
Spain OEL - TWA Listed
Sweden OEL - TWAs Listed
8. EXPOSURE CONTROLS / PERSONAL PROTECTION
The exposure limit(s) listed for solid components are only relevant if dust may be generated.


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State: Film-coated tablets</th>
<th>Color: White Blue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula: Mixture</td>
<td>Molecular Weight: Mixture</td>
</tr>
</tbody>
</table>

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

- Stability: Stable under normal conditions of use.
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

**Atorvastatin calcium**
- Rat/Mouse Oral LD50 > 5000 mg/kg
- Rabbit Dermal LD50 > 2000 mg/kg

**Calcium carbonate**
- Rat Oral LD50 6450 mg/kg
11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose
Rat  Oral  LD50  > 5000 mg/kg
Rabbit  Dermal  LD50  > 2000 mg/kg

Magnesium stearate
Rat  Oral  LD50  > 2000 mg/kg
Rat  Inhalation  LC50  > 2000 mg/m³

Silicon dioxide, NF
Rat  Oral  LD50  10 g/kg

Polysorbate 80
Rat  Oral  LD50  25 g/kg

Amlodipine besylate
Rat (M)  Oral  LD50  393 mg/kg
Rat (F)  Oral  LD50  686 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Atorvastatin calcium
Skin Sensitization - Beuhler  Guinea Pig  Negative
Skin Irritation  Rabbit  Non-irritating
Eye Irritation  Rabbit  Mild

Microcrystalline cellulose
Skin Irritation  Rabbit  Non-irritating
Eye Irritation  Rabbit  Non-irritating

Amlodipine besylate
Eye Irritation  Rabbit  Severe
Skin Irritation  Rabbit  Non-irritating
Skin Sensitization - GPMT  Guinea Pig  Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Atorvastatin calcium
104 Week(s)  Dog  Oral  10 mg/kg/day  LOAEL  Liver
13 Week(s)  Mouse  Oral  100 mg/kg/day  LOAEL  Liver
52 Week(s)  Rat  Oral  5 mg/kg/day  NOAEL  Liver
13 Week(s)  Rat  Oral  5 (male); 20 (female) mg/kg/day  NOAEL  Liver

Amlodipine besylate
3 Month(s)  Rat  Oral  3 mg/kg/day  NOAEL  Adrenal gland, Heart
1 Month(s)  Rat  Oral  3.5 mg/kg/day  LOEL  Heart
1 Year(s)  Rat  Oral  2 mg/kg/day  NOAEL  Adrenal gland Heart

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))
11. TOXICOLOGICAL INFORMATION

**Atorvastatin calcium**
- Reproductive & Fertility: Rat Oral 20 mg/kg/day NOAEL Negative
- Fertility and Embryonic Development: Rat Oral 100 mg/kg/day NOAEL Negative
- Embryo / Fetal Development: Rat Oral 4 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity
- Embryo / Fetal Development: Rabbit Oral 10 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity, Fetotoxicity
- Peri-/Postnatal Development: Rat Oral 20 mg/kg/day NOAEL Fetotoxicity

**Amlodipine besylate**
- Fertility and Embryonic Development: Rat Oral 25 mg/kg/day NOAEL Not teratogenic, Maternal toxicity
- Peri-/Postnatal Development: Rat Oral 25 mg/kg/day NOAEL Fetotoxicity, Fetal mortality
- Prenatal & Postnatal Development: Rabbit Oral 25 mg/kg/day NOAEL Not Teratogenic

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Atorvastatin calcium**
- In Vitro Bacterial Mutagenicity (Ames): *Salmonella*, E. coli Negative
- In Vivo Micronucleus: Mouse Bone Marrow Negative

**Amlodipine besylate**
- Bacterial Mutagenicity (Ames): *Salmonella*, E. coli Negative
- In Vivo Cytogenetics: Mouse Bone Marrow Negative
- In Vitro Cytogenetics: Mouse Bone Marrow Negative
- In Vitro Chromosome Aberration: Human Lymphocytes Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Atorvastatin calcium**
- 104 Week(s): Mouse Oral 200 mg/kg/day NOAEL Not carcinogenic
- 104 Week(s): Rat Oral 100 mg/kg/day NOAEL Not carcinogenic

**Amlodipine besylate**
- 24 Month(s): Rat Oral, in feed 2.5 mg/kg/day NOAEL Not carcinogenic, No effects at maximum dose
- 24 Month(s): Mouse Oral, in feed 0.5 mg/kg/day NOAEL Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**Silicon dioxide, NF**
- IARC: Group 3

12. ECOLOGICAL INFORMATION

**Environmental Overview:** This formulation has not been tested as a whole, the following apply to component substance(s): Based on the concentration of the active ingredient in the formulation, No harmful effects to aquatic organisms are expected.

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

**Atorvastatin calcium**
- *Daphnia magna* (Water Flea): EC50 48 Hours 200 mg/L
12. ECOLOGICAL INFORMATION

Aquatic Toxicity Comments:
A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Species, Method, End Point, Duration, Result)

Atorvastatin calcium
- Aspergillus niger (Fungus) MIC > 1000 mg/L
- Trichoderma viride (Fungus) MIC > 1000 mg/L
- Clostridium perfringens (Bacterium) MIC 100 mg/L
- Activated sludge OECD EC50 >1000 mg/L

Amlodipine besylate
- Nostoc sp. (Freshwater Cyanobacteria) MIC 20 mg/L
- Aspergillus Niger MIC > 100 mg/L
- Trichoderma viride MIC > 100 mg/L
- Clostridium perfringens MIC >100 mg/L
  - Bacillus subtilis MIC 80 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified
## 15. REGULATORY INFORMATION

**OSHA Label:**
Non-hazardous in accordance with international standards for workplace safety.

### Canada - WHMIS: Classifications

**WHMIS hazard class:**
Class D, Division 2, Subdivision B

<table>
<thead>
<tr>
<th>Material Name</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>REACH - Annex IV - Exemptions from the obligations of Register:</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch, pregelatinized</td>
<td>Listed</td>
<td>Listed</td>
<td>Present</td>
<td>232-679-6</td>
</tr>
<tr>
<td>Silicon dioxide, NF</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
<td>231-545-4</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>Listed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
<td>232-674-9</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>REACH - Annex IV - Exemptions from the obligations of Register:</th>
<th>Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>207-439-9</td>
</tr>
</tbody>
</table>

Magnesium stearate

<table>
<thead>
<tr>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (AICS):</td>
<td>Listed</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>209-150-3</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

- R22 - Harmful if swallowed.
- R41 - Risk of serious damage to eyes.
- R51 - Toxic to aquatic organisms.

Reasons for Revision:

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification.
Updated Section 3 - Composition / Information on Ingredients.
Updated Section 4 - First Aid Measures.
Updated Section 5 - Fire Fighting Measures.
Updated Section 7 - Handling and Storage.
Updated Section 8 - Exposure Controls / Personal Protection.
Updated Section 12 - Ecological Information.
Updated Section 13 - Disposal Considerations.
Updated Section 15 - Regulatory Information.

Prepared by:

Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet